Neuren Financial Statements From 2010 to 2025
| NURPF Stock | USD 12.89 0.00 0.00% |
Check Neuren Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neuren Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Neuren financial statements analysis is a perfect complement when working with Neuren Pharmaceuticals Valuation or Volatility modules.
Neuren |
Neuren Pharmaceuticals Limited Company Return On Equity Analysis
Neuren Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Neuren Pharmaceuticals Return On Equity | -0.27 |
Most of Neuren Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neuren Pharmaceuticals Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Neuren Pharmaceuticals Limited has a Return On Equity of -0.2746. This is 98.85% lower than that of the Healthcare sector and 99.25% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 11.42% lower than that of the firm.
Neuren Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Neuren Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Neuren Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Neuren Pharmaceuticals competition to find correlations between indicators driving Neuren Pharmaceuticals's intrinsic value. More Info.Neuren Pharmaceuticals Limited is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Neuren Pharmaceuticals' earnings, one of the primary drivers of an investment's value.About Neuren Pharmaceuticals Financial Statements
Neuren Pharmaceuticals stakeholders use historical fundamental indicators, such as Neuren Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Neuren Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Neuren Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Neuren Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Neuren Pharmaceuticals Limited. Please read more on our technical analysis and fundamental analysis pages.
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. The company was incorporated in 2001 and is based in Camberwell, Australia. Neuren Pharmaceutica operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Neuren Pink Sheet
Neuren Pharmaceuticals financial ratios help investors to determine whether Neuren Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Neuren with respect to the benefits of owning Neuren Pharmaceuticals security.